CD33 and cancer: In another recent study sunitinib reduced non-classical CD33+ CD14+ CD16+ MDSCs in the blood of cancer patients by apoptosis and the rest of CD33+ CD14+ CD16+ MDSCs showed less pSTAT3, ArgI and less suppressive activity on T-cell proliferation.